Core Insights - Rani Therapeutics has demonstrated that oral semaglutide via the RaniPill® HC (RT-116) shows comparable bioavailability, pharmacokinetics, and weight loss effects to subcutaneous administration [1][3][9] - The RaniPill platform is gaining recognition for its potential to facilitate oral delivery of various obesity treatments, with plans for a Phase 1 study of RT-114, a GLP-1/GLP-2 dual agonist, expected to start in 2025 [1][10] Company Overview - Rani Therapeutics is a clinical-stage biotherapeutics company focused on developing technologies for the oral delivery of biologics and drugs, specifically through the RaniPill capsule [11] - The company aims to replace subcutaneous injections with oral dosing, enhancing patient convenience and adherence [11] Product Details - Semaglutide, a GLP-1 receptor agonist, mimics the activity of the GLP-1 hormone, which regulates appetite and food intake [2] - Currently, semaglutide is available only as a subcutaneous injection marketed as WEGOVY, with global sales of approximately $3.1 billion in the first half of 2024 [3][4] Study Findings - In a preclinical study, semaglutide was successfully delivered in 7 of 8 canines using the RaniPill capsule, showing comparable pharmacokinetic and pharmacodynamic profiles to subcutaneous administration [6][7] - The relative bioavailability of oral semaglutide was found to be 107% compared to subcutaneous administration, with both methods resulting in similar weight loss and reductions in serum triglycerides and cholesterol [9] Future Prospects - The company is optimistic about the potential of a once-weekly oral version of semaglutide to transform obesity treatment, providing a more convenient option for patients [4][3] - The initiation of the Phase 1 clinical trial for RT-114 is anticipated in 2025, further expanding Rani's obesity treatment portfolio [10]
Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill® HC